Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 15.53 USD -0.96% Market Closed
Market Cap: 2B USD

Aurinia Pharmaceuticals Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aurinia Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
EPS (Diluted)
$0
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
-5%
Repare Therapeutics Inc
NASDAQ:RPTX
EPS (Diluted)
-$1
CAGR 3-Years
-43%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
EPS (Diluted)
-$3
CAGR 3-Years
-31%
CAGR 5-Years
-38%
CAGR 10-Years
-38%
Willow Biosciences Inc
TSX:WLLW
EPS (Diluted)
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
45%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
EPS (Diluted)
CA$0
CAGR 3-Years
-55%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
No Stocks Found

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Biotechnology

In the heart of the pharmaceutical world, Aurinia Pharmaceuticals Inc. has carved out a niche with its focus on tackling autoimmune diseases, primarily targeting lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus. This Canadian company made waves with the development and approval of its flagship product, Lupkynis (voclosporin), an oral medication designed to treat this specific condition. By addressing a critical unmet need for patients grappling with the debilitating effects of lupus nephritis, Aurinia not only provides a precious lifeline for many but also positions itself as a significant player within the rare disease market. The development of Lupkynis was not just a scientific endeavor; it was a strategic move backed by rigorous clinical trials that underscored the efficacy and safety needed to gain regulatory approval and, ultimately, market trust. Aurinia’s revenue stream is primarily generated through the commercialization of Lupkynis, which has proved crucial in building its financial foundation. The company has embraced a commercialization strategy that involves direct sales, supported by partnerships and collaborations that enhance its reach and distribution capabilities. This approach allows Aurinia to maintain a strong connection to the markets it serves, providing valuable insights into emerging patient needs and market trends. Meanwhile, the company’s robust pipeline reflects its commitment to innovation, featuring additional immunology-focused therapies that could, over time, broaden its portfolio and potentially unlock new revenue streams. Integral to Aurinia’s success is its strategic focus on niche areas where the competition may be limited, giving it a distinctive edge in the complex world of pharmaceutical development.

AUPH Intrinsic Value
HIDDEN
Show

See Also

What is Aurinia Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
0.6 USD

Based on the financial report for Sep 30, 2025, Aurinia Pharmaceuticals Inc's EPS (Diluted) amounts to 0.6 USD.

Back to Top